Next Article in Journal
Quality of Life in Patients with NSCLC Receiving Maintenance Therapy
Next Article in Special Issue
Complications from Stereotactic Body Radiotherapy for Lung Cancer
Previous Article in Journal
Effects of Age on the Detection and Management of Breast Cancer
Previous Article in Special Issue
Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer
Article Menu

Export Article

Open AccessReview
Cancers 2015, 7(2), 930-949; doi:10.3390/cancers7020816

Targeted Therapies in Non-Small Cell Lung Cancer—Beyond EGFR and ALK

Medical Oncology, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland
Academic Editor: Siow Ming Lee
Received: 27 February 2015 / Revised: 7 May 2015 / Accepted: 13 May 2015 / Published: 26 May 2015
(This article belongs to the Special Issue Non-Small Cell Lung Cancer Therapies)
View Full-Text   |   Download PDF [150 KB, uploaded 29 May 2015]


Systemic therapy for non-small cell lung cancer (NSCLC) has undergone a dramatic paradigm shift over the past decade. Advances in our understanding of the underlying biology of NSCLC have revealed distinct molecular subtypes. A substantial proportion of NSCLC depends on oncogenic molecular aberrations (so-called “driver mutations”) for their malignant phenotype. Personalized therapy encompasses the strategy of matching these subtypes with effective targeted therapies. EGFR mutations and ALK translocation are the most effectively targeted oncogenes in NSCLC. EGFR mutations and ALK gene rearrangements are successfully being targeted with specific tyrosine kinase inhibitors. The number of molecular subgroups of NSCLC continues to grow. The scope of this review is to discuss recent data on novel molecular targets as ROS1, BRAF, KRAS, HER2, c-MET, RET, PIK3CA, FGFR1 and DDR2. Thereby the review will focus on therapeutic strategies targeting these aberrations. Moreover, the emerging challenge of acquired resistance to initially effective therapies will be discussed. View Full-Text
Keywords: lung cancer; targeted cancer therapy; oncogene; ROS1; c-MET; RET; BRAF; HER2; FGFR1; DDR2 lung cancer; targeted cancer therapy; oncogene; ROS1; c-MET; RET; BRAF; HER2; FGFR1; DDR2
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Rothschild, S.I. Targeted Therapies in Non-Small Cell Lung Cancer—Beyond EGFR and ALK. Cancers 2015, 7, 930-949.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top